Search Results - antonella+antignani

2 Results

Sort By:

Summary: The NCI seeks research co-development partners or licensees for monoclonal antibodies that specifically target cancer-expressed EGFR. Description of Technology: Epidermal growth factor receptor (EGFR) is a well-known oncogenic driver in lung cancer, head and neck cancer, glioblastoma multiforme (GBM) and other cancers. NCI inventors have...

Published: 2/5/2026 | Updated: 2/5/2026 | Inventor(s): David Fitzgerald, Antonella Antignani, Robert Sarnovsky

Keywords(s):

Category(s): TherapeuticArea > Oncology, Application > Therapeutics, Collaboration Sought > Licensing, Collaboration Sought > Collaboration

EGFRvIII Antibodies for the Treatment of Human Cancer

Summary: The NCI seeks research co-development partners or licensees for monoclonal antibodies that specifically target cancer-expressed EGFR. Description of Technology: Epidermal growth factor receptor variant III (EGFRvIII) is a variant of EGFR that is an excellent target for immunotherapy because of its expression in cancer cells and not in normal...

Published: 4/24/2026 | Updated: 8/2/2023 | Inventor(s): David Fitzgerald, Antonella Antignani, Eric Ho, Robert Sarnovsky

Keywords(s): ADC, Antibody-drug Conjugate, CAR, chimeric antigen receptor, EGFR, EGFRvIII, Epidermal Growth Factor Receptor, Epidermal growth factor receptor variant III, FitzGerald, Recombinant Immunotoxins, RITs

Category(s): Application > Therapeutics, TherapeuticArea > Oncology, Collaboration Sought > Collaboration, Collaboration Sought > Licensing